Skip to main content
Toggle navigation
Login
Search
Home
Browse by Poster Title
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
NUM
Sort by
Title
A
Favorite
141
A Comparative Analysis of Pharmacokinetics of Oncology Drugs Between Healthy Volunteers & Patients With Cancer
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
A002
A Comparative Review of Study Population & Dose Recommendations for In Vivo Bioequivalence Studies With Pharmacokinetic Endpoints Between FDA & EMA Guidances
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
034
A Drug-Drug Interaction Study Between ABBV-903 & Midazolam in Healthy Participants
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
124
A Drug-Drug Interaction Study to Evaluate the Impact of Coadministration of AZD0780 on Rosuvastatin Exposure in Healthy Participants
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
122
A Literature Review on the Performance of Tiny Tract for In Vitro Modeling to Predict Food-Drug & pH-Dependent Drug-Drug Interaction Risks
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
027
A Quantitative Evaluation of the Relationship Between Hepatic Extraction Ratio & Change in Plasma Half-Life Following Modulation of CYP3A Activity
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
095
A Survey of Pharmacodynamic Biomarkers Bioanalysis in 20 Biologics License Applications Approved for Enzyme Replacement Therapy Indications
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
A009
A Translational Platform Quantitative Systems Pharmacology Model for Preclinical to Clinical Translation of In Vivo CRISPR-Cas9 Gene Therapy
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
A009
A Translational Platform Quantitative Systems Pharmacology Model for Preclinical to Clinical Translation of In Vivo CRISPR-Cas9 Gene Therapy
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
062
Absolute Oral Bioavailability of Nerandomilast in Healthy Male Study Participants
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
167
Acetaminophen Prescribing & Pharmacokinetic Analysis in Children, Adolescents & Young Adults With Cancer
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
116
Addressing Disparities in Clinical Trial Participation: A Comparative Analysis of Cardiovascular & Oncology Studies
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
077
Advanced Waveform Analysis of ECG Signals to Characterise Cardiac Drug Safety Between Caucasian & Japanese Volunteers
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
074
A First-in-Human, Single & Multiple Ascending Dose Study of CK-4021586, A Novel Cardiac Myosin Inhibitor
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
117
Analyzing Drug-Drug Interaction Risk Assessment Strategies for Protein Therapeutics in Inflammatory Bowel Disease: A Literature-Based Evidence Review
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
094
Analyzing First-in-Human Trial Designs of Antisense Oligonucleotides: A Preliminary Review Across Subcutaneous, Intravenous & Intrathecal Routes of Administration
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
014
Analyzing the Association Between Single Nucleotide Polymorphisms & Combinations of Buprenorphine & Associated Metabolite Concentrations
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
137
Application of Lactation Physiologically-based Pharmacokinetic Modeling to Predict Exposure of Select Compounds
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
040
Assessment of Clinical Challenges With Application of Institute for Safe Medication Practices Targeted Medication Safety Best Practice: Injectable Promethazine
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
049
Assessment of the Effect of HBV Viral Genotype on Bepirovirsen Efficacy Using a Population Pharmacokinetic/Pharmacodynamic Modeling Approach
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
123
Assessment of Impact of CYP3A4 Inducers on Investigational Drugs Informed By Clinical Drug-Drug Interaction Data: A Survey of Drugs Approved By FDA
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
C
Favorite
A004
Cefepime Population Pharmacokinetics Using Volumetric Absorptive Microsampling in Critically Ill Children With Multiple Organ Dysfunction Syndrome
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
A004
Cefepime Population Pharmacokinetics Using Volumetric Absorptive Microsampling in Critically Ill Children With Multiple Organ Dysfunction Syndrome
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
015
Characterizing the Covariates & their Impacts on Statistical Evaluations of Clinical Pharmacology Studies in the 351(k) Biologic License Applications
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
033
Clinical Assessment of Mocravimod as a Victim of Drug-Drug Interactions via CYP3A Metabolism & Transporters
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
022
Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy Participants
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
130
Clinical Outcomes of Carfilzomib-based Chemotherapy by Relative Dose Intensity in Patients with Relapsed or Refractory Multiple Myeloma
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
065
Clinical Pharmacological Characterization of Cilta-cel, a CAR-T Therapy Directed Against BCMA in Adult Patients With Multiple Myeloma in a Multicohort CARTITUDE-2 Study
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
019
Clinical Pharmacology Insights into Dosing Strategies of Approved Antibody-Drug Conjugates
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
073
Clinical Pharmacology of Bemarituzumab in Gastric & Gastroesophageal Junction Cancer Patients Supports the Interchangeability of Q2W & Q3W Dosing Regimens
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
091
Clinical Pharmacology of Bispecific T-cell Engagers: A Summary Based on FDA Approvals
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
096
Cluster Analysis to Identify Biomarkers of Treatment Response Following Sirolimus Treatment for HIV Cure
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
156
Comparable Pharmacokinetics of Sacituzumab Govitecan Between Patients With Metastatic Urothelial Cancer & Metastatic Triple-Negative Breast Cancer
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
016
Comparative Pharmacokinetics & Bioequivalence Study of Gatifloxacin 200mg Tablets
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
097
Comparison of Hypoxia Inducible Factor-1A Polymorphisms Between Chronic Kidney Disease Patients & Healthy Subjects
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
161
Comparison of Nicotine Pharmacokinetic & Subjective Profiles of Three Modern Oral Nicotine Products & a Snus Product
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
A001
Comparison of the Pharmacokinetics/Pharmacodynamics of a Fixed-Dose Combination of Rabeprazole/Magnesium Oxide 20/350 mg to the Enteric-Coated Rabeprazole 20 mg
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
053
Concentration-QTc Analysis of Quemliclustat in Combination With/Without Zimberelimab & nab-Paclitaxel/Gemcitabine in Patients With Advanced Pancreatic Cancer
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
092
Concentration-QTc Interim Analysis of I-DXd in Subjects With Advanced Solid Tumors from Study IDeate-Pantumor01 (DS7300-A-J101)
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
098
CYP2B6 & CYP2C19 Phenotypes Influence Sertraline Exposure in Children & Adolescents
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
D
Favorite
165
Demographic Composition of New Molecular Entities Approved by the United States FDA Between 2017 & 2023 to Treat Type 2 Diabetes
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
088
Developing a Physiologically-based Pharmacokinetic Model Across Various Species Exploring Drug Interaction Potential of Mitragynine
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
087
Development of a Pharmacokinetic-Tumor Target Engagement Model Using Nonclinical Data to Inform Phase 1 Dosing Scheme for a Novel Bispecific CD40-EpCAM Antibody, KK2269
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
A007
Dose Optimization of Cefazolin in Adult Cardiac Surgery With Cardiopulmonary Bypass After Albumin Supplementation
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
A007
Dose Optimization of Cefazolin in Adult Cardiac Surgery With Cardiopulmonary Bypass After Albumin Supplementation
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
028
Drug-Drug Interactions of Lirafugratinib
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
E
Favorite
126
Effect of a Moderate CYP3A4 Inducer on the Pharmacokinetics of Omaveloxolone in Healthy Subjects
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
044
Effect of Food on the Pharmacokinetics & Safety Profile of p53 Reactivator Rezatapopt in Healthy Subjects & Patients With Solid Tumors Harboring a
TP53
Y220C Mutation
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
111
Effect of Food on the Pharmacokinetics, Safety & Tolerability of Budesonide Oral Suspension in Healthy Adults: A Randomized Phase 1 Study
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
120
Effect of Herbal Medicines on the Pharmacokinetics of Donepezil
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
037
Effect of Omaveloxolone @ Its Metabolites on Corrected QT Interval in Health Subjects
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
133
Effect of Probiotics on the Levels of Neuroendocrine Biomarkers – A Systematic Review & Meta-Analysis
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
030
Effects of Itraconazole & Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
043
Effects of the Innate Immune System, Body Habitus & Sex on the Pharmacokinetics & Antitumor Response of Anetumab Ravtansine in Patients With Solid Tumors
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
105
ENA-001, a Novel BK-channel Blocker, Enhances Hypoxic Ventilatory Sensitivity and Alleviates Propofol-induced Respiratory Effects in Healthy Volunteers
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
036
Endogenous Biomarker Use in Renal Transporter-Mediated Drug Interactions: A Literature Review of Intrinsic, Extrinsic Factors & Disease Impact on Biomarker Levels
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
A003
Enhanced HLA-B*15:02 Screening Before Carbamazepine Therapy in Vietnam: Advancements in Real-Time PCR TaqMan Probe Procedure
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
118
Evaluation of Drug-Drug Interaction in Nested Patient Studies
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
071
Evaluation of Palbociclib & Combinatorial Chemotherapy Pharmacokinetics in Pediatric Patients With Recurrent or Refractory Solid Tumors
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
011
Evaluation of Prompt Engineering Strategies for Pharmacokinetic Data Analysis With the ChatGPT Large Language Model
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
081
Exclusion of Pediatric Patients With Renal Impairment in Clinical Trials for Antiviral Products
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
084
Exploration of Estimated Renal Function & Gabapentin Clearance in Older Adults
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
079
Exploring the Impact of Hepatic Impairment on the Pharmacokinetics of New Molecular Entities: A Comprehensive Analysis of Labeling Information
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
138
Exposure-Response Analyses of Efficacy & Safety of Trastuzumab Deruxtecan to Inform Dosing Recommendation in HER2-mutant Non-Small Cell Lung Cancer
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
046
Exposure-Response Analysis to Inform QT Prolongation Potential for Cedirogant
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
F
Favorite
023
FDA & EMA Regulatory Recommendations on Fed Bioequivalence Study in Healthy Subjects vs Patients for Generic Drug Development
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
166
Fetal & Neonatal Drug Exposure Following Nipocalimab Treatment in Pregnant Women at Risk of EOS-HDFN
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
061
First-in-Human Evaluation of Pharmacokinetics & Safety of Tilpisertib Fosmecarbil, an Oral Prodrug of a Tumor Progression Locus 2 Inhibitor, in Healthy Volunteers
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
076
First-in-Human Phase 1 SAD, MAD, Food Effect & DDI Study of SGR-1505, a Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 Inhibitor, in Healthy Volunteers
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
055
First-in-Human Population PKPD Modelling & Simulation of CUE-101: Preliminary Results
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
106
First-in-Human Safety, Pharmacokinetics & Pharmacodynamics of the Oral Factor D Inhibitor BCX10013
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
128
Food & Formulation Effect of a Novel Src Homology Region 2 Domain−containing Protein Tyrosine Phosphatase 2 (SHP2) Allosteric Inhibitor in Combination With Pembrolizumab
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
G
Favorite
151
Genome-Wide CpG Methylation Profiling of Leukemia Cells Treated With Curcuminoids
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
163
GLP-1-Induced Delays in GI Motility & Their Effects on Co-Administered Drug Absorption: A PBPK Analysis
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
H
Favorite
047
How Much PK Data Do We Really Need in Phase 3? A Milvexian Case Study
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
I
Favorite
129
Identification of Factors Associated With Vancomycin-Induced Acute Kidney Injury: An Analysis Using a Common Data Model
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
139
Imaging-based Anti-HIV Antibody Exposure in Anorectal Tissue Is More Closely Linked to Protective Efficacy During Clinical Prevention Trials
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
A005
Implications of Being Born Small for Gestational Age on the Exposure of Vancomycin & Gentamicin In Neonates
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
A005
Implications of Being Born Small for Gestational Age on the Exposure of Vancomycin & Gentamicin In Neonates
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
039
Incidence & Predictors of Stroke Mimic Amongst Patients Treated With Recombinant Tissue Plasminogen Activator: A Retrospective Comparison
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
020
Integration of the National HIV Curriculum at Accredited Graduate Programs of Pharmacy
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
080
Is it Time to Retire Cockcroft-Gault & “Original” Schwarz Formulas in Drug Development?
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
L
Favorite
142
Landscape Analysis of Dose Optimization Approaches in Oncology Investigational New Drug (IND) Submissions in 2023
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
038
Lorundrostat Concentration-QTc Results from the First-in-Human Study in Healthy Participants Demonstrate Lack of Relevant Effect & Replaces the Thorough QT Study
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
M
Favorite
082
Mechanistic Physiologically-based Pharmacokinetic Modeling to Predict Bictegravir Drug Disposition in Pregnancy
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
A006
Microfluidic Blood-Milk Barrier & Physiologically-based Pharmacokinetic Model to Predict Lofexidine Secretion into Breast Milk
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
A006
Microfluidic Blood-Milk Barrier & Physiologically-based Pharmacokinetic Model to Predict Lofexidine Secretion into Breast Milk
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
149
Milvexian Does Not Prolong the QTc Interval: A Thorough QT Study in Healthy Subjects
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
A010
Model-Based Assessment of the Contribution of Fc Proteins & Serum Proteins to the Elevated Clearance of Monoclonal Antibodies
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
A010
Model-Based Assessment of the Contribution of Fc Proteins & Serum Proteins to the Elevated Clearance of Monoclonal Antibodies
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
158
Model-Informed Development of Recombinant
Erwinia
Asparaginase (JZP458) in Patients With Acute Lymphoblastic Leukemia
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
160
Modeling Age-related Changes in Kidney Function Using Aminoglycoside Clearance as a Surrogate: Can Body Composition Help?
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
050
Modeling Effects of Lymphodepletion Therapy on CAR T-cell & Cytokine Dynamics
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
N
Favorite
131
Network Analysis of Sedative Medication Use in a Canadian Cohort of People Living with HIV: Uncovering Potential Sedative Medication Drivers of Frailty States
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
052
Nipocalimab Pharmacokinetic/Pharmacodynamic & Exposure-Response Modeling in Pregnancies at Risk for Early-onset Severe (EOS) HDFN
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
025
No Clinically Meaningful Drug Interaction Between Futibatinib & Digoxin, Rosuvastatin or Quinidine
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
164
No Clinically Relevant Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Lirafugratinib
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
031
No Increase in the Risk of Liver or Muscle Toxicity in Pegozafermin-treated Patients With Metabolic Dysfunction-Associated Steatohepatitis on Statin Background Therapy
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
O
Favorite
146
Optimizing Simvastatin Dosing in Patients Post-gastric Bypass Surgery Using a Population PK/PD Link Approach
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
121
Organic Anion Transporter 3 Mediated Interactions in a Renal Proximal Tubule Epithelial Cellular Model: Effects of Mycophenolate & Prednisolone
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
P
Favorite
059
Perioperative Antibiotic Prophylaxis in Paediatric Cardiac Surgery – is One Day Sufficient to Prevent Surgical Site Infections?
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
017
Pharmacist Administered Parenteral Medications: A Descriptive Study of a Novel Inpatient Training Program
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
152
Pharmacoeconomic Analysis of Therapeutic Regimens Used for Treatment of Psoriasis in India
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
107
Pharmacokinetic & Immunogenicity Results from the China Cohort of the MAJESTEC-1 Study of Teclistamab for Relapsed/refractory Multiple Myeloma
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
068
Pharmacokinetic Analyses & Population Pharmacokinetic Modeling of Maplirpacept in Patients With Newly Diagnosed Acute Myeloid Leukemia
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
114
Pharmacokinetic Characterization of Flotetuzumab in Pediatric Patients With Refractory/Relapsed Acute Myeloid Leukemia
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
109
Pharmacokinetic Comparison Between Fixed-dose Combination of Rosuvastatin/Ezetimibe 2.5/10 mg & the Coadministration of Individual Formulations in Healthy Subjects
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
108
Pharmacokinetic Comparison of Ezetimibe/Rosuvastatin/Telmisartan Fixed-dose Combination vs Coadministration of Separate Treatments
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
060
Pharmacokinetic Modeling of the IRF5 Antisense Oligonucleotide JNJ-66525433 & IRF5 mRNA Expression in Healthy Individuals
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
051
Pharmacokinetically-Guided Dosing of Fludarabine for Lymphodepletion in CAR T-cell Therapy: A Clinical Trial Simulation Study
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
140
Pharmacokinetic-Pharmacodynamic Analysis of Cytokines in First-in-Human Phase 1 Dose Escalation Study of the MALT-1 Inhibitor, SGR-1505, in Healthy Volunteers
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
157
Pharmacokinetics & Exposure-Response Analyses of Revumenib Support Dosing in a Broad Population of Patients With Relapsed/Refractory Acute Leukemias
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
042
Pharmacokinetics & Exposure-safety Analyses Across Tumor Types for Ifinatamab Deruxtecan (I-DXd) in the First-in-Human Study IDeate-Pantumor01 (DS7300-A-J101)
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
072
Pharmacokinetics & Pharmacodynamics of Milvexian After Administration Every 12 Hours in Healthy Subjects
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
112
Pharmacokinetics & Safety of Teclistamab Administered in the Arm or Thigh of Patients With Relapsed/Refractory Multiple Myeloma in MajesTEC-1
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
064
Pharmacokinetics of 6-diazo-5-oxo-L-norleucine (DON) in Malawian Healthy Adults & Adults With Uncomplicated Malaria
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
162
Pharmacokinetics of DYP688 in Patients With Metastatic Uveal Melanoma & Other GNAQ/11 Mutant Melanomas
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
154
Pharmacokinetics of Sacituzumab Govitecan in Japanese Patients With Advanced Solid Tumors
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
083
Pharmacokinetics of Tenofovir Alafenamide, Emtricitabine & Dolutegravir in a Patient on Peritoneal Dialysis
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
090
Pharmacokinetics of Tetrahydrocannabinol in Infants Exposed to Breastmilk from Recreational Cannabis Users
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
159
Pharmacokinetics, Pharmacodynamics & Safety of Budigalimab, An Anti-PD-1 Monoclonal Antibody, in People Living With HIV-1
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
078
Pharmacokinetics, Pharmacodynamics & Safety of Rusfertide, A Hepcidin Mimetic, in Subjects With Hepatic Impairment & in Subjects With Renal Impairment
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
113
Pharmacokinetics, Safety & Tolerability of GS-1427, a Pro-drug of a Potent & Selective Small-Molecule α4β7 Integrin Inhibitor, in Healthy Volunteers
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
110
Phase 1, Single-Center, Randomized, Placebo-Controlled, Partially Blinded, Single Ascending Dose Study on the Effects of Troriluzole on corrected QT in Healthy Subjects
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
026
Phase I Open Label Study to Evaluate the Effects of Savolitinib on the Pharmacokinetics of P-gp, OATP1B1/3, OCT2, MATE1/2K & OAT1/3 Substrates in Healthy Volunteers
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
127
Phase I Open Label Study to Evaluate the Effects of Strong CYP1A2 Inhibitor on Savolitinib Pharmacokinetics in Healthy Volunteers
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
029
Physiologically-based Pharmacokinetic Modeling of a Novel HER3-Targeted Antibody-Drug Conjugate, Patritumab Deruxtecan to Assess Pharmacokinetic Drug-Drug Interaction
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
145
Physiologically-based Pharmacokinetic Models of Opioid in Pregnancy, Maternal-Fetal, Pediatrics & Breastfeeding Mothers: A Systematic Literature Review
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
135
Population Kinetic-Pharmacodynamic Modeling of Multiple Lipid Biomarker Responses to Zodasiran in Patients With Mixed Dyslipidemia
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
041
Population Modeling Framework With Adaptive Dosing for Optimizing Clinical Utility of Compounds in Development for Treatment of Solid Tumors
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
070
Population Pharmacokinetic & Exposure-Response Analyses for the Phase 3 PhALLCON Study of Ponatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
066
Population Pharmacokinetic Analysis of Cenobamate
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
048
Population Pharmacokinetic and Exposure-response Analyses of anti-BDCA2 Antibody Litifilimab Support Its Clinical Benefit for Cutaneous Lupus Erythematosus
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
144
Population Pharmacokinetic Model for Tulisokibart in Healthy Participants
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
136
Population Pharmacokinetics & Pharmacodynamics of Pegozafermin, a Novel GlycoPEGylated FGF21, in a Phase 2 Study in Severe Hypertriglyceridemia
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
069
Population Pharmacokinetics of Bictegravir in Pregnant & Postpartum Persons Living With HIV
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
045
Population Pharmacokinetics of GB-5001, a Long-acting Intramuscular Injection of Donepezil, in Healthy Participants
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
075
Population Pharmacokinetics of Trastuzumab Deruxtecan (T-DXd) in Subjects With HER2-mutant & HER2-overexpressing Non-Small Cell Lung Cancer (NSCLC)
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
153
Population Pharmacokinetics/Pharmacodynamics Modeling of INCAGN02385 in Patients With Select Advanced Malignancies
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
035
Potential Epigenetic Opioid-Chemotherapy Drug Interactions
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
063
Preclinical & Clinical Pharmacokinetics of JNJ-75220795, A siRNA Therapeutic Targeting
PNPLA3
, for Metabolic-associated Steatohepatitis
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
085
Predicting Metoprolol Exposure-Response in Pregnant Population Using Physiologically-based Pharmacokinetic Modeling
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
125
Pregabalin-codeine-disease Interactions in Patients With Acute Herpetic or Postherpetic Neuralgia
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Q
Favorite
119
Quantitative Assessment of Drug-Drug Interaction (DDI) Potential of BIIB122 on Oral Contraceptives Using a Physiologically-based Ppharmacokinetic Model
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
056
Quantitative Systems Pharmacology Model Predicts Combination Activity of CD19-targeted Loncastuximab Tesirine With Epcoritamab in B-cell Lymphoma
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
057
Quantitative Systems Pharmacology Modeling of Loncastuximab Tesirine Combined With Mosunetuzumab & Glofitamab Guides Dosing in B-cell Lymphoma
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
R
Favorite
147
Real-World Insights into Drug Dosing Patterns for Commonly Prescribed Drugs During Pregnancy
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
S
Favorite
100
Sex-Related Differences in the Pharmacokinetics of Therapeutic Proteins
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
102
Sisunatovir Inhibition of Multiple Ion Channel Subtypes Prevents the Risk for QT Prolongation Due to hERG Channel Inhibition
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
021
Strategic & Quantitative Recommendations on Bioanalytical Cross-Validation Experiment Design from a Clinical Pharmacology Perspective
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
132
Strategic Selection of Clinical Trial Core Outcomes Customized to Disease & Drug Therapy: Examples Generated During coreVWD & coreHEM Initiatives
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
T
Favorite
024
The Drug-Drug Interaction Effect of Steady State Rifampin Exposure on Single Dose Pharmacokinetics of Lazertinib
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
032
The Effect of an Acid-reducing Agent, Esomeprazole on Sparsentan Pharmacokinetics in Healthy Volunteers
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
054
The Effect of Moderate Hepatic Impairment on ONC201 (Dordaviprone) Pharmacokinetics
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
143
The Effect of Severe Renal Impairment on ONC201 (Dordaviprone) Pharmacokinetics
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
115
The Effectiveness of Anmarin, an Antimycotic Herbal Drug: Preclinical & Clinical Studies
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
150
The Gut-immune-liver Axis in Patients With Alcohol Use Disorder & Clinically Low Serum Zinc Levels
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
155
The Human Metabolism of Lufotrelvir, a Prodrug for the Treatment of SARS-COV2, Investigated By LC+AMS
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
089
The Impact of COVID-19 Mediated Bidirectional Dysregulation of CYP3A4 on Systemic & Pulmonary Candidate Drug Concentrations
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
067
The Impact of Late-Runner Participants on PK Variability in Healthy Volunteer, Single-Ascending Dose Trials
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
148
The Mechanism of Action of an Innovative Respiratory Stimulant, ENA-001
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
101
The SARS-CoV-2 Mpro Inhibitor Ibuzatrelvir is a Substrate but not an Inducer nor Inhibitor of CYP3A
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
093
Trends in First-in-Human Trials of Intrathecal Antisense Oligonucleotide Therapies: Insights into Dose Selection, Dose Escalation & Early Clinical Development
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
U
Favorite
013
Use of Artificial Intelligence in Drug Development
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
A008
Using Clinical Data & Physiologically-based Pharmacokinetic Modelling to Assess the Effect of Hepatic Impairment on Avapritinib Pharmacokinetics to Guide Dose Adjustment
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
A008
Using Clinical Data & Physiologically-based Pharmacokinetic Modelling to Assess the Effect of Hepatic Impairment on Avapritinib Pharmacokinetics to Guide Dose Adjustment
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
